SUBSCRIBE
SUBSCRIBE

Synexa Life Sciences

Synexa Life Sciences is a biomarker and bioanalytical lab CRO, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays.

With a team of over 200 staff across three global laboratory locations; Manchester, Turku (Finland) and Cape Town, we provide innovative solutions to support our customers to achieve their clinical milestones.

Our main areas of expertise include biomarker identification and development, large and small molecule clinical bioanalysis, (soluble) biomarker analysis (utilising MSD, LC-MS/MS, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry, ELISpot and Fluorospot) and genomic services to support clinical trials and translational studies.

We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis.

NEWS
iStock, quantic69
PARTNERED WITH VIVA BIOTECH
Building the Next Generation of Biologics: Inside the Future of Protein Engineering
As bispecifics, ADCs, protein degraders, and AI-designed mini-proteins move into the clinic, discovery teams face a new bottleneck: engineering and producing molecules whose complexity challenges conventional workflows.
December 1, 2025
 · 
9 min read
 · 
BioSpace Insights
Businessmen helping their friend climbing the rock, teamwork, partnership in business concept
Cell Therapy
6 Companies Hanging On in Cell Therapy
As big pharmas including Takeda and Novo Nordisk flee the cell therapy space and smaller biotechs shutter their operations, these players are sticking around to take the modality as far as it can go.
December 1, 2025
 · 
9 min read
 · 
Tristan Manalac
A scientist with pill bottles in front of FDA headquarters
Regulatory
FDA Action Alert: BMS, GSK, Amgen and More
The FDA’s docket in December includes decisions for two big biologic franchises: BMS’s Breyanzi and Amgen’s Uplizna.
December 1, 2025
 · 
5 min read
 · 
Tristan Manalac
Sponsored
Cracking the Code: Solving Microbial Manufacturing’s Biggest Challenges
Perfecting microbial manufacturing processes means taming its greatest asset: speed. This rapid process for creating biologics also means a race against time, where success hinges on conquering three key challenges: designing a robust microbial strain, optimizing fermentation for industrial scale, and ensuring consistent high-yield product yield.
December 1, 2025
 · 
6 min read
 · 
AGC Biologics
Abstract arrow direction. Technology background. High speed. Hi-tech.
Rare diseases
As New Hereditary Angioedema Drugs Flood the Market, Will Uptake Match Innovation?
This year has seen the approval of several first-in-class therapies for HAE, but in a fragmented space, experts question whether they will be enough to net their developers a significant share of the entrenched market.
December 1, 2025
 · 
5 min read
 · 
Ben Hargreaves
Concept World kidney day, handcraft paper blue kidneys and stethoscope on yellow background. Copy space. Banner.
Approvals
Otsuka Secures IgAN Win as FDA Approves First Anti-APRIL Antibody
Analysts at Guggenheim Partners expect Voyxact to see “broad commercial uptake” given its relatively broad label compared with previous accelerated approvals for IgA nephropathy.
November 26, 2025
 · 
2 min read
 · 
Tristan Manalac
Stack of coins balancing on seesaw over a bottle of pills.
Drug pricing
Novo’s GLP-1s Highlight List as CMS Unveils Final Prices For Second Cycle of Drug Negotiations
The discounts should be compared against the drugs’ “ultimate net price” rather than their indicated list price to gauge the true impact of the negotiations, BMO Capital Markets analysts said.
November 26, 2025
 · 
2 min read
 · 
Tristan Manalac
Female hand showing thumbs up gesture on blue background, art collage. Positive hand sign. Fashion collage in the style of Thumbs up magazine. Contemporary art. Modern design.
Approvals
AstraZeneca Notches Another Indication for Imfinzi, Pushing PD-L1 Blocker Into Stomach Cancer
Imfinzi is the first immunotherapy approved for perioperative use to treat gastric and gastroesophageal junction cancers.
November 26, 2025
 · 
2 min read
 · 
Tristan Manalac
A scientist in blue gloves holding white abino lab laboratory mouse to conduct an experiment and test vaccine.
Insights
Are Animals Out? How NAMs Are Changing the Rules of the Game 
A coordinated national effort is emerging to bring alternatives to animal testing into routine preclinical use, backed by a fresh FDA roadmap and a global coalition of scientific and industry partners. 
November 26, 2025
 · 
7 min read
 · 
BioSpace Insights
Load More
Visit website
Email Us
IN THE PRESS
Press Releases
Waters Sets a New Benchmark for Robustness and Sensitivity for High-Throughput Labs with the Xevo TQ Absolute XR Mass Spectrometer
June 2, 2025
 · 
4 min read
BioMidwest
Inotiv, Inc. Announces New Site Openings and Expansions Supporting Additional Capacity and Service Offerings
December 8, 2022
 · 
4 min read
Business
Parexel Announces Strategic Collaboration with Synexa Life Sciences and Drawbridge Health for COVID-19 Clinical Serology Testing Solution
November 2, 2020
 · 
4 min read
JOBS